ÂÜÀòÂÒÂ×

Peter is Principal at Decheng Capital, which he joined in October 2016. In addition to this expertise in finance, investment, transaction, operational, and drug development, he brings a passion to find a cure for cancer and bring life-saving drugs to patients. Prior to joining Decheng, Peter held positions in business and corporate development, sales and marketing, and company startups. As Associate at Frazier Healthcare Ventures, he led the investment and company formation for Silvergate Pharmaceuticals, a pediatric rare disease company that to date has launched four internally developed and proprietary products, and served as Vice President of Business Development & Managed Care at the company. At Frazier, he was involved in and served as a board observer for Calistoga Pharmaceuticals, VentiRx, Alnara Pharma, and Oceana Therapeutics, as well as several of the firm’s public investments. Prior to Frazier, he served in the Morgan Stanley and Cowen Healthcare Investment Banking groups. Mr. Colabuono holds a B.A. in Molecular Biology and Biochemistry from Dartmouth College is an inventor and author on issued patents and journal articles and is active with the Head & Neck Cancer Alliance.